It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aberrant expansion of KRT5+ basal cells in the distal lung accompanies progressive alveolar epithelial cell loss and tissue remodelling during fibrogenesis in idiopathic pulmonary fibrosis (IPF). The mechanisms determining activity of KRT5+ cells in IPF have not been delineated. Here, we reveal a potential mechanism by which KRT5+ cells migrate within the fibrotic lung, navigating regional differences in collagen topography. In vitro, KRT5+ cell migratory characteristics and expression of remodelling genes are modulated by extracellular matrix (ECM) composition and organisation. Mass spectrometry- based proteomics revealed compositional differences in ECM components secreted by primary human lung fibroblasts (HLF) from IPF patients compared to controls. Over-expression of ECM glycoprotein, Secreted Protein Acidic and Cysteine Rich (SPARC) in the IPF HLF matrix restricts KRT5+ cell migration in vitro. Together, our findings demonstrate how changes to the ECM in IPF directly influence KRT5+ cell behaviour and function contributing to remodelling events in the fibrotic niche.
Idiopathic pulmonary fibrosis has been associated with aberrant expansion of KRT5-expressing basal cells. Here the authors show how changes in the ECM glycoprotein SPARC restrict the movement of KRT5+ cells, affecting their retention within fibrotic tissue.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Imperial College London, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK (GRID:grid.420545.2)
2 Imperial College London, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
3 Imperial College London, Facility for Imaging by Light Microscopy, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
4 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196)
5 The University of Manchester, Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
6 Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK (GRID:grid.420545.2); Nottingham University Hospitals NHS Trust, City Campus, Department of Respiratory Medicine, Nottingham, UK (GRID:grid.240404.6) (ISNI:0000 0001 0440 1889)
7 Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK (GRID:grid.420545.2)
8 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
9 Imperial College London, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Keck Medicine of USC, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)